Pulmonary Disorders Flashcards

1
Q

What is Community Acquired Pneumonia and what are the 2 most common causes?

A

1. acquired outside of the hospital setting & patient is not a resident of a long term care facility OR

2. patient that was ambulatory prior to admission who develops pneumonia within 48 hours of initial hospital admission

1. Streptococcus pneumoniae

2. Haemophilus influenzae

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is Hospital Acquired (nosocomial) Pneumonia?

A

pneumonia occurring > 48 hrs after hospital admission

often caused by Pseudomonas, MRSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Atypical Pneumonia Organisms: Mycoplasma

A

MYCOPLASMA:** ear pain, **bullous myringitis, erythematous pharynx or TM. Persistent nonproductive cough

Send _serum cold agglutins_ as part of the diagnostic workup

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Atypical Pneumonia Organisms: Chlamydophila

A

hoarseness, fever ⇒ respiratory symptoms after a few days

send IgM, IgG titers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Atypical Pneumonia Organisms: Legionella

A

Legionella: associated with GI Sx, î LFTs, hyponatremia

send legionella urine antigens + PCR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Chest XRAY of typical pneumonia** vs. **atypical pneumonia

A

typical pneumonia: lobar pneumonia

atypical pneumonia: diffuse, patchy interstitial or reticulonodular infiltrates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Diagnostic Workup of Pneumonia

A

A. CXR/CT Scan: CXR resolution may lag behind clinical improvment for weeks. A pleural effusion may be present (usually exudative)

  1. abscess formation ⇒ S. aureus, Klebsiella, anaerobes
  2. Upper lobe (especially R upper lobe) with bulging fissure, cavitations ⇒ Klebsiella

B. Sputum (gram stain/culture): utility debated. Gross sputum may reveal clues to pathogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Physical Exam of Pneumonia

A

dullness to percussion

INCREASED fremitus

Bronchial breath sounds, EGOPHONY*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment for CAP outpatient

A

Macrolide or Doxycycline 1st line**

Fluoroquinolones are only used first line if comorbid conditions/recent Abx use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treatment for CAP, inpatient

A

ß lactam + macrolide (or doxycycline)

OR

broad spectrum FQ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the PCV13 Pneumococcal conjugate vaccine? (Prevnar)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is Asthma?

A

reversible hyperirritability of the tracheobronchial tree ⇒ airway inflammation & bronchoconstriction

MC chronic childhood disease (10%)

1/2 develop < 10 y of age, another 1/3 by 40 yo

atopy is a risk factor*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is Samter’s Triad?

A

1. asthma

2. nasal polyps

3. ASA/NSAID allergy

associated with atopic dermatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pathophysiology of asthma

A

1. AIRWAY HYPERREACTIVITY:

extrinsic (allergic); associated with increased IgE

intrinsic (idiosyncratic): nonallergic triggers: infection (viral, URI), pharmacologic, occupational, exercise, emotional, cold air

2. BRONCHOCONSTRICTION: airway narrowing secondary to smooth muscle constriction, bronchial wall edema, and thick mucus secretion, collagen deposition, smooth muscle/mucosal hypertrophy

(brochoconstriction leads to air trapping)

decreased expiratory airflow

3. INFLAMMATION: secondary to cellular infiltration (T lymphocytes, neutrophils, eosinophils) & their pro-inflammatory cytokines (leukotrienes)

increased histamine from mast cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clinical Manifestations of Asthma

A

Classic Triad

1. dyspnea 2. wheezing 3. cough (esp @ night)

Physical Examination

1. prolonged expiration with wheezing, hyperresonance to percussion, decreased breath sounds, tachycardia, tachypnea, accessory muscle use

2. _severe asthma and status asthmaticus:_ inability to speak in full sentences, PEFR < 40% predicted, altered mental status, pulsus paradoxus (inspiratory, decreased SBP > 10), cyanosis, “tripod” position, “silent chest” (no air exchange)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Diagnostic Studies for Asthma

A

A. PULMONARY FUNCTION TEST: GOLD STANDARD

reversible obstruction (decreased FEV1, decreased FEV1/FVC)

B. Bronchoprovocation: methacholine challenge test (> 20% decrease in FEV1) + Bronchodilator challenge test ( > 12% increase in FEV1)

C. Peak Expiratory Flow Rate (PEFR): best and most objective way to assess asthma exacerbation severity & patient response in ED (PEFR > 15% from initial attempt = response to treatment)

D. Pulse Oximetry: < 90% indicative of respiratory distress

E. ABG

F. CXR: usually not helpful but can be used to rule out other etiologies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Management of Asthma: Quick Relief of Acute Exacerbation (Rescue Drugs)

A

1. Short Acting ß2 agonists (SABA): 1st line treatment

Albuterol

MOA: bronchodilator

SE: ß1 cross reactivity: tachycardia/arrhythmias, muscle tremors, CNS stimulation, hypokalemia

2. Anticholinergics

Ipratropium

MOA: central bronchodilator, inhibits nasal mucosal secretions

SE: thirst, blurred vision, dry mouth, urinary retention, dysphagia, acute glaucoma, BPH

3. Corticosteroids

predniose, methylprednisolone, prednisolone

MOA: anti-inflammatory. all but the mildest exacerbations should be discharged on a short course of oral corticosteroids (3 - 5 days)

SE: immunosuppression, catabolic, hyperglycemia, fluid retention, osteoporosis, growth delays

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Management of Asthma: Long-Term (chronic control) maintenance

A

1. Inhaled Corticosteroids (ICS)

beclomethasone, flunisolide, triamcinolone

  • Drug of choice for long term persistent asthma*
  • MOA: cytokine & inflammation inhibition*
  • SE: thrush*

2. Long-Acting ß2 Agonists (LABA)

Salmeterol, ICS/LABA Combo:Symbicort (Budesonide, Formoterol), Advair diskus (Fluticasone/ Salmeterol)**

  • long acting ß2 agonists added to steroids ONLY if persistent asthma is not controlled with ICS alone*
  • NOT used in acute exacerbations and LABAs are NOT used alone*

3. Mast Cell Modifiers

Cromolyn, Nedocromil

MOA: inhibits mast cell and leukotriene-mediated degranulation. used as prophylaxis only

inhibits acute phase response to cold air, exercise, sulfites

4. leukotriene modifiers/receptor antagonists (LTRA)

montelukast, zafirlukast, zileuton

useful in asthmatics with allergic rhinitis/aspirin induced asthma. prophylaxis only

SE: minimal, increased LFTs, HA, GI myalgias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Management of Asthma: adjuncts

A

IV Magnesium

bronchodilator

(decreased Ca2+-mediated smooth muscle contraction)

Heliox

decreases airway resistance because helium + oxygen is lighter than room air

Ketamine

IV anesthetic that has sedative, analgesic, and bronchodilator effects. may be useful as an induction, sedative agent in young, otherwise healthy population of intubated patients

OMALIZUMAB:

anti-IgE antibody** (inhibits IgE inflammation) **used in severe, uncontrolled asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Classification of Mild Persistent Asthma

A
  • Sx > 2 days/week (but not daily)
  • SABA use > 2 days/week (but not more than 1x per day)
  • nighttime awakenings 3 - 4x per month
  • minor limitation with activity
  • FEV1 > 80% predicted
  • FEV1/FVC normal

Management: inhaled SABA prn + low dose ICS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Classification of Moderate Persistent Asthma

A
  • Sx daily
  • SABA use daily
  • nighttime awakenings > 1x/wk (but not nightly)
  • some limitation with activity
  • FEV1 60 - 80% predicted
  • FEV1/FVC reduced by 5%

Management: Low dose ICS + LABA

or

Increase ICS dose (medium)

  • or*
  • Add LTRA*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Classification of Severe Persistent Asthma

A
  • Sx throughout the day
  • SABA use several times a day
  • nighttime awakenings often, usually nightly
  • extremely limited activity
  • FEV1 < 60%
  • FEV1/FVC reduced by > 5%

Management: High dose ICS + LABA

+ Omalizumab (anti-IgE drug)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Step Down/Step Up System for Asthma

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is a pneumothorax?

A

air in the pleural space

increasingly positive pleural pressure causes collapse of the lung

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Types of **Pneumothorax: Spontaneous**
atraumatic and idiopathic. due to ***bleb rupture*** ***1. Primary: no underlying lung disease\*.*** *mainly affects ****_t_**all, thin men 20 - 40 yo, smokers,** _+_ family history of pneumothroax* ***2.***
26
Types of **Pneumothorax: traumatic**
* **_iatrogenic_:** during CPR, thoracentesis, PEEP (ventilation), subclavian line placement * _other trauma_: car accidents, etc.
27
Types of **Pneumothorax: Tension**
any type of pneumothorax in which the ***positive air pressure pushes lungs, trachea, great vessels & heart to the _CONTRALATERAL SIDE_*** ## Footnote * immediately life-threatening* * MC seen during trauma, mechanical ventilation or resuscitative efforts*
28
Clinical Manifestations of **Pneumothorax**
1. ***_Chest pain_:*** *usually **_pleuritic, unilateral,_ non-exertional*** & sudden in onset; ***Dyspnea*** 2. **_PHYSICAL EXAM_** * **_Hyperresonance to percussion_*****, decreased fremitus, decreased breath sounds*** over affected side * unequal respiratory expansion, tachycardia, tachypnea * **_tension pneumothorax:_ increased JVP, pulsus paradoxus, hypotension**
29
Diagnosis of **Pneumothorax**
**CXR with _expiratory view_ preferred** -- decreased peripheral lung markings (due to collapsed lung tissue) -- **_+_ companion lines** (visceral pleural line running parallel with the ribs) -- deep sulcus sign on supine chest radiograph (air collection basally and anteriorly)
30
Management of **Pneumothorax**
1. **_Observation:_ *in primary spontaneous if small ( \< 15 - 20%*** *the diameter of the hemithorax or _\<_ 2 - 3 cm between the chest wall & lung on CXR). Observe at least 6 hours with repeat CXR to affirm no progression + 24 - 48 hour F/U. often spontaneously resolves w/i 10 days* * -- O2 shown to increase air resorption 3 - 4x faster than 1.25% every day* * 2.* **_Chest tube placement (thoracostomy):_ if large or severe sx** 3. **_Needle aspiration:_ if tension pneumothorax\* followed by chest tube placement.** Needle placed in 2nd ICS @ midclavicular line on the affected side * *avoid pressure changes ex: high altitudes, smoking, unpressurized aircraft & scuba diving*
31
What is **Pertussis? (whooping cough)**
***highly contagious infection secondary to Bordatella pertussis*** * rarely seen due to widespread vaccination. Gram negative coccobaccillus.* * MC seen in children \< 2 yo*
32
Clinical Manifestations of **Pertussis (whooping cough)**
**catarrhal phase ⇒ paroxysmal phase ⇒ convalescent phase** **1. catarrhal phase:** URI Sx lasting 1 - 2 weeks. most contagious during this phase **2. paroxysmal phase:** *severe paroxysmal coughing fits with _inspiratory whooping sound after fits_* ***_+_** **post coughing emesis*** *may develop subconjunctival hemorrhage from the increased pressure due to coughing fits* **3. convalescent phase:** resolution of cough (coughing stage may last up to 6 wks)
33
Management of **Pertussis (whooping cough)**
***_supportive treatment mainstay\*_*** oxygenation, nebulizers, mechanical ventilation as needed ***_antibiotics_*** used to decrease contagiousness within the 1st 7 days of Sx onset--also often given to exposed contacts **_Macrolides:_ erythromycin, azithromycin**
34
Diagnosis of **Pertussis (whooping cough)**
1. _PCR of nasopharnygeal swab_: GOLD STANDARD. performed in the first 3 wks of Sx onset 2. **Lymphocytosis\*** 60 - 80% lymphocytes on differential. WBC count may be as high as 50,000
35
What is **acute bronchiolitis**?
***lower respiratory tract infection*** *of the **small ariways*** ⇒ proliferation/necrosis of the bronchiolar epithelium produces obstruction from the sloughed epithelium. increased mucus plugging & submucosal edema leading to ***_peripheral airway narrowing & variable obstruction_***
36
What is the **MC** cause of **acute bronchiolitis**?
**_respiratory synctial virus (RSV)_** (50 - 70%) ***RSV part of parayxovirus family\**** other: adenovirus, influenza, parainfluenza, _+_ mycoplasma pneumonia, chlamydia trachomatis
37
What are the risk factors for **acute bronchiolitis?**
***infants \< 2 yo MC affected (esp ~ 2 months)*** * \< 6 months of age exposure ot cigarettes, lack of breastfeeding, premature (\< 37 wks gestation) & crowded conditions* * MC in fall and spring*
38
Clinical Manifestations of **acute bronchiolitis**
***_fever, URI Sx 1 - 2 days ⇒ repiratory distress_*** (wheezing, tachypnea, nasal flaring, cyanosis, retractions _+_ rales)
39
Diagnosis of **acute bronchiolitis**
_CXR:_ hyperinflation, peribroncbial cuffing, etc. nasal washings using monoclonal Ab testing ***pulse ox single best predictor of disease in children*** (\< 96% ⇒ ADMIT TO HOSPITAL)
40
Management of **acute bronchiolitis**
***1. _supportive:_ humidified O2 mainstay of treatment*** *delivered by mask, tent, or hood. IV fluids. Acetaminophen/ibuprofen for fever. mechanical ventilation if severe.* ***2. Medications:** **play a limited role*** *_+_ ß agonists, _+_ nebulized racempic epi* *corticosteroids NOT indicated unless history of reactive airway disease* ***3. Ribavarin _+_ administered if severe lung or heart disease or in immunosuppressed patients***
41
**_Prevention_** for **Acute Bronchiolitis**
***_Palivizumab prophylaxis may be used in increased risk groups_*** ***_HAND WASHING_*** RSV is highly contagious and is transmitted via direct contact with secretions and self-inoculation by contaminated hands
42
What is **acute epiglottitis**?
inflammation of epiglottitis that may interfere with breathing **medical emergency**
43
Causes of **acute epiglottitis**
***_HAEMOPHILUS INFLEUNZAE TYPE B_*** **(Hib) MC\*\*\*** reduced incidence due ot Hib vaccination. may rarely be caused by *Streptococcus pneumoniae, S. aureus, GABHS* * MC in children 3 mnths - 6 yrs* * Males 2x MC* * DM is a risk factor in adults...*
44
Diagnosis of **acute epiglottitis**
* ***_Laryngoscopy: definitive Dx\*\*_*** *provides direct visualization but may provoke spasm* _Cherry red epiglottits with swelling_ * **_Lateral cervical radiograph: THUMB SIGN_** * * ***_if high suspicion, do not attempt to visualize the epiglottits with a tongue depressor in children_***
45
Clinical Manifestations of **acute apiglottitis**
**_3 Ds_ - **_D_**ysphagie, **_D_**rooling, **_D_**istress** fever, ***odynophagia, _inspiratory stridor_****, dyspnea, hoarseness, muffled voice, **_tripoding_*** suspect in pt with rapidly developing pharyngitis, muffled voice & odynophagia (painful swallowing) out of proportion to physical findings
46
Management of **acute epiglottitis**
**_1. Maintaining the airway & supportive management is the mainstay of Tx_** place child in a comfortable position dexamethasone to reduce airway edema tracheal intubatiodn to protect the airway in severe cases **2. Antibiotics: 2nd/3rd cephalosporins: ceftriaxone or cefotaxime** _+_ add PCN, ampicillin, or anti-staphylococcal coverage
47
What is **laryngotracheitis (croup)**?
***inflammation MC secondary to acute viral infection of the UPPER AIRWAY*** *(larynx, subglottis, trachea)* *⇒* ***_subglottic larynx/trachea swelling_*** * ⇒* * stridor, BARKING cough, hoarseness*
48
What is the MC cause of **laryngotracheitis (croup)?**
**_PARAINFLUENZA type 1 MC cause\*\*_** also...adenovirus, RSV, rhinovirus, etc. Diptheria rare 15% of children experience croup in childhood (MC 6 months - 6 yrs) MC in fall/winter
49
Clinical Manifestations of **laryngotracheitis (croup)**
***_Barking cough (seal-like, harsh)_*** ***stridor*** both inspiratory and expiratory (worsened by crying or agitating the child) ***hoarseness*** due to laryngitis ***dyspnea*** (especially ***worse at night***) **_+_ URI Sx** either preceding or concurrent fever
50
Diagnosis of **laryngotracheitis (croup)**
clinical Dx (once epiglottitis and foreign body aspiration are excluded) _Frontal **cervical radiograph**: **STEEPLE SIGN\*\***_ (subglottic narrowing of trachea) - 50%
51
Management of **laryngotracheitis (croup)**
1. **Mild:** (no stridor at rest, no respiratory distress): **cool, humidified air mist, hydration** **Dexamethasone provides significant relief** as early as 6 hours after single dose 2. **Moderate:** (stridor at rest with mild to moderate retractions): Dexamethasone PO or IM + supportive treatment _+_ nebulized Epi * should be observed for 3 - 4 hours of clinical intervention* 3. **_Severe:_** (stridor at rest with marked retractions) ***Dexamethasone + nebulized Epi and hospitalization***
52
What is **influenza?**
Acute repiratory illnesses caused by Influenza A or B viruses. part of the orthomyxovirus family ## Footnote ***A is associated with more severe, extensive outbreaks*** *spreads primarily via airborne respiratory secretions. outbreaks occur mainly in the fall/winter*
53
Clinical Manifestations of **influenza**
**_usually abrupt onset_** of a wide range of sx: HA, fever, chills, malaise, URI Sx, pharyngitis, pneumonia ## Footnote *Myalgias MC seen in legs and lumbosacral area*
54
Diagnosis of **influenza**
usually clinical ## Footnote **rapid influenza test (nasal swab) or viral culture can be performed**
55
Management of **influenza**
***1. _supportive mainstay tx in healthy patients_*** (acetaminophen, rest) 2. ***antivirals usually only needed in patients with high risk of complications*** ***best if initiated _within 48 hours of sx onset_*** A. Neuraminidase Inhibitors--oseltamivir (tamiflu) (vs. A and B) B. Amantadine and Rimantidine (vs. A, not commonly used)
56
**_Prevention of Influenza_**
57
What is **acute bronchitis?**
acute bronchitis is defined by a **_cough which persists for MORE THAN 5 days_** (fever is unusual; if your patient has a fever, consider PNA) 95% will be viral cause
58
Although 95% of **acute bronchitis** is **viral**, some bacterial causes are...
M. Cattarhalis (common bacterial cause of acute bronchitis) H. influenzae S. pneumoniae
59
What is the organism for tuberculosis and how can you get it?
*Mycobacterium tuberculosis* chronic infection leading to **granuloma formation** **inhalation of airborne droplets** ⇒ mycobacterium reaches the alveoli & are ingested by alveolar macrophages
60
classic findings of **tuberculosis**
**fever, night sweats, anorexia, weight loss**
61
What is secondary (reactivation) TB and where is the MC location?
***reactivation of latent TB with waning immune defenses*** *5 - 10% lifetime incidence* ***MC localized in apex/upper lobes with cavitary lesions*** ***THESE PATIENTS ARE CONTAGIOUS***
62
What is the screening test for TB and how is it interpreted?
Purified Protein Dertivative (PPD): ***examine 48 - 72 hours for transverse induration (redness is NOT considered positive)*** _POSITIVE IF:_ **\> 5 mm: HIV +**, or immunosuppressed (ex. prednisone 15 mg/day \> 1 mnth) close contacts of patients with active TB CXR consistent with old/healed TB (calcified granuloma) **\> 10 mm:** all other high risk populations/high prevalence populations (prison, homeless) **\> 15 mm:** pts with no risk factors
63
Diagnostic Studies in suspected cases of active TB
**1. (GOLD STANDARD) _Acid-fast smear & sputum cultures x 3 days:_** TB ruled out after 3 negative smears **2. CXR are indicated to excluse active TB (newly + PPD) and used as yearly screening in patients with known + PPD**
64
On a CXR where are the MC places for TB to occur? (reactivation, primary, and miliary TB)
* **_Reactivation:_** apical (upper lobe) * **_Primary TB:_** middle/lower lobe * **_Miliary TB (widespread dissemination):_** CXR shows small **millet-seed** like nodular lesion (2 - 4 mm)
65
Miliary TB is TB spread outside the lungs. What are some names for this?
**Potts Dz** is Tb to the spine **Scrofula** is Tb to the cervical lymph nodes
66
RIPE Treatment for TB
**Rifampin (RIF)** (orange-colored secretions) **Isoniazid (INH)** (hepatitis, *_peripheral neuropathy prevented by pyridoxine B6)_* **Pyrazinamide (PZA)** (hepatitis and hyperuricemia, photosensitive rash) **Ethambutol (EMB)** (optic neuritis) or **Streptomycin (STM)** (ototoxicity and nephrotoxicity) *_INH prophylaxis given to children \< 4 yo with exposure to contacts with active disease_*
67
**Mycobacterium avium complex (MAC)**
Mycobacterium avium and intracellulare _Transmission:_ soil/water (NOT person to person) Sx occur RARELY in immunocompetent pts. **seen in HIV when _CD4 \< 50\*\*_**
68
Clinical Manifestations of **Mycobacterium Avium Complex (MAC)**
1. **_Pulmonary Infection:_** in immunocompetent: cough with sputum, fever, weight loss, **bronchiectasis** 2. **_Disseminated:_** (in HIV pts) FUO, sweating, weight loss, fatigue, diarrhea, dyspnea, RUQ pain 3. **_Lymphadenitis in children:_** cervical submandibular/maxillary
69
Diagnosis and Management of **Mycobacterium Avium Complex (MAC)**
**_Dx:_** Acid-fast bacillus staining & culture **_Management:_** _Clarithromycin + Ethambutol_ at least 12 months
70
What is another name for enterobiasis?
Pinworms!!
71
Clinical Manifestations of **enterobiasis (pinworms)**
**perianal itching especially nocturnal** | (eggs are laid at night)
72
Diagnosis and Mangement of **enterobiasis (pinworms)**
**_Dx:_** *scotch tape test (early in AM)* to look for eggs under a microscope **_Management:_** **Albendazole or Mebendazole** none are used in children _\<_ 2 yo
73
What is **Cystic Fibrosis?**
autosomal recessive disorder that results in the **abnormal production of mucus by almost all exocrine glands, causing obstruction of those glands and ducts** lungs are generally histologically normal at birth, but **most pts develop pulmonary disease beginning in infancy or early childhood** **non-pulmonary** - pancreatitis and steatorrhea - **pts will need supplementation of fat-soluble vitamins** the course is characterized by episodic exacerbations with infection and progressive decline in pulmonary function -- **mean survival is about 31 years**
74
Diagnosis and Management of Cystic Fibrosis
**elevated quantitative sweat chloride test** performed on two different days **increased NaCl \> 60 mEq/L** a normal result does not exclude the diagnosis, if strongly suspected, **DNA testing can provide definitive Dx** **CXR may reveal hyperinflation, mucus plugging and focal atelactasis** **_Management_:** in the first few months of life, respiratory infection is common with **Staph aureus** and **Haemophilus influenzae** AFTER THAT **Pseudomonas** aeruginosa **becomes the major causative organism for infections** therapies focus on: * clearing the airway of secretions -- **chest physiotherapy** * reversing bronchoconstriction * treating respiratory infections **(treat for pseudomonas)** *